HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: Frequency, severity, and treatment bias

Arthritis and Rheumatism

Volumn 46, Issue 9, 2002, Pages 2320-2329

  Fries, James F ^a,d   Wolfe, Frederick ^b   Apple, Raymond ^c   Erlich, Henry ^c   Bugawan, Teodorica ^c   Holmes, Tyson ^a   Bruce, Bonnie ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; EPITOPE; ETANERCEPT; GOLD; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOSITY; HLA TYPING; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SEROLOGY; TREATMENT INDICATION;

ALLELES; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; EPITOPES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX;

EID: 0036743993     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10485     Document Type: Article

References (34)

1. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995;95:2120-6.
2. McMahon MJ, Hillarby MC, Clarkson RW, Hollis S, Grennan DM. Major histocompatibility complex variants and articular disease severity in rheumatoid arthritis. Br J Rheumatol 1993;32:899-902.
3. Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994;37:1166-70.
4. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001;44:1736-43.
5. MacGregor A, Ollier W, Thomson W, Jawaheer D, Silman A. HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995;22:1032-6.
6. Reveille JD, Alarcón GS, Fowler SE, Pillemer SR, Neuner R, Clegg DO. HLA-DRB1 genes and disease severity in rheumatoid arthritis. Arthritis Rheum 1996;39:1802-7.
7. Seidl C, Koch U, Buhleier T, Frank R, Moller B, Markert E, et al. HLA-DRB1*04 subtypes are associated with increased inflammatory activity in early rheumatoid arthritis. Br J Rheumatol 1997;36:941-4.
8. Rau R, Herborn G, Zueger S, Fenner H. The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years. J Rheumatol 2000;27:2566-75.
9. Eberhardt K, Fex E, Johnson U, Wollheim FA. Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis. Ann Rheum Dis 1996;55:34-9.
10. Suarez-Almazor ME, Tao S, Moustarah F, Russell AS, Maksymowych W. HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid arthritis: association with susceptibility but not severity in a city wide community based study. J Rheumatol 1995;22:2027-33.
11. Thomson W, Harrison B, Ollier B, Wiles N, Payton T, Barrett J, et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum 1999;42:757-62.
12. Citera G, Padulo LA, Fernandez G, Lazaro MA, Rosemffet MG, Maldonado Cocco JA. Influence of HLA-DR alleles on rheumatoid arthritis: susceptibility and severity in Argentine patients. J Rheumatol 2001;28:1486-91.
13. Mattey DL, Hassell AB, Dawes PT, Cheung NT, Poulton KV, Thomson W, et al. Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001;44:1529-33.
14. Wagner U, Kaltenhäuser S, Sauer H, Arnold S, Seidel W, Häntzschel H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40:341-51.
15. Van Jaarsveld CHM, Otten HG, Jacobs JWG, Kruize AA, Brus HLM, Bijlsma JWJ. Association of HLA-DR with susceptibility to and clinical expression of rheumatoid arthritis: re-evaluation by means of genomic tissue typing. Br J Rheumatol 1998;37:411-6.
16. Criswell LA, Mu H, Such CL, King MC. Inheritance of the shared epitope and long-term outcomes of rheumatoid arthritis among community-based Caucasian females. Genet Epidemiol 1998;15:61-72.
17. Fries JF, Williams CA, Singh G, Ramey DR. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. J Rheumatol 1997;24:838-44.
18. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
19. Sokka T, Hannonen P. Utility of disease-modifying anti-rheumatic drugs in "sawtooth" strategy: a prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 1999;58:618-22.
20. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
21. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
22. Fries JF, Spitz PW, Mitchell DM, Roth SH, Wolfe F, Bloch DA. Impact of specific therapy upon rheumatoid arthritis. Arthritis Rheum 1986;29:620-7.
23. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
24. Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol 1992;148:249-58.
25. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
26. Christensen R. Log-linear models. New York: Springer-Verlag; 1990.
27. Neter J, Wasserman W, Kutner MH. Applied linear statistical models. Homewood (IL): Irwin; 1985.
28. Manly FJ. Randomization, bootstrap and Monte Carlo methods in biology. 2nd ed. London: Chapman and Hall; 1997.
29. Good P. Permutation tests. New York: Springer-Verlag; 1994.
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
31. Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 2000;27:1139-47.
32. Mu H, Chen JJ, Jiang Y, King M-C, Thomson G, Criswell LA. Tumor necrosis factor α microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope. Arthritis Rheum 1999;42:438-42.
33. Kroot EJ, van Gestel AM, Swinkels HL, Albers MM, van de Putte LB, van Riel PL. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol 2001;28:1511-7.
34. Ferraccioli GF, Casatta L, Bartoli E, De Vita S, Dolcetti R, Boiocchi M, et al. Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. Arthritis Rheum 1995;38:867-8.